Skip to main content
Top
Published in: PharmacoEconomics 6/2003

01-04-2003 | Original Research Article

Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease

For Quebec Residents Aged 2 Months to 20 Years

Authors: Carol Rancourt, Jean-Pierre Grégoire, W. Robert Simons, Alain Dostie

Published in: PharmacoEconomics | Issue 6/2003

Login to get access

Abstract

Objective: To evaluate the most efficient approach to managing an outbreak of serogroup C meningococcal disease. An early planned mass immunisation programme (MIP) was compared with a delayed programme implemented at the peak of a meningococcal outbreak.
Design and setting: A cost-benefit model was constructed of meningococcal cases reported in Quebec, Canada, from 1990–1993, before and after the MIP, during the winter of 1992–1993, when 84% of residents aged 6 months to 20 years were vaccinated. Epidemiological data from 1990–1993 were transposed to 2002–2003 under the assumption that Quebec is on the brink of an identical outbreak cycle. All Quebec residents aged 2 months to 20 years were assumed to be vaccinated, which required a total of 1.7 million doses of conjugated vaccine. Clinical and economic outcomes of both vaccination scenarios were compared. All costs were transformed to 2001 Canadian dollars ($Can), at an annual inflation rate of 3%. Future earnings due to premature death were discounted at 5% per year with a 3% increase in wages per year and a 9% unemployment rate.
Perspective: Ministry of Health and society.
Main outcome measures: The number of new cases avoided and the prevention of hospital and societal costs due to meningococcal disease-attributed premature mortality and morbidity, and direct costs associated with implementation of a MIP.
Results: When compared with a delayed MIP over a 14-month period, an early planned MIP would have prevented 112 new cases of meningococcal disease (16 deaths, 21 major complications) while saving $Can37.1 million in total direct costs to the Ministry of Health and an additional $Can17.4 million in societal costs in the province of Quebec.
Conclusion: An early planned MIP implemented in Quebec in September 2001, should be cost beneficial compared with delaying mass immunisation until a meningococcal outbreak is underway. Although this conclusion is limited by the assumption that epidemiological trends in 2001 in absence of a MIP would have been similar to that observed in the early 1990s prior to the MIP, the analysis still indicates that an early MIP in the 1990s would have been cost beneficial compared with a delayed MIP.
Footnotes
1
The use of tradenames is for product identification purposes only and does not imply endorsement.
 
Literature
1.
go back to reference Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6 (2): 118–36PubMed Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6 (2): 118–36PubMed
2.
go back to reference Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344 (18): 1378–88PubMedCrossRef Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344 (18): 1378–88PubMedCrossRef
3.
go back to reference Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis 1998; 26 (5): 1159–64PubMedCrossRef Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada, 1990–1994. Clin Infect Dis 1998; 26 (5): 1159–64PubMedCrossRef
4.
go back to reference De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177–81PubMedCrossRef De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285 (2): 177–81PubMedCrossRef
5.
go back to reference De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ 1996; 74 (4): 407–11PubMed De Wals P, Dionne M, Douville-Fradet M, et al. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bull World Health Organ 1996; 74 (4): 407–11PubMed
7.
go back to reference Canadian Consensus Conference on Meningococcal Disease. Guidelines for control of meningococcal disease: laboratory centre for disease control. CMAJ 1994; 150 (11): 1825–39 Canadian Consensus Conference on Meningococcal Disease. Guidelines for control of meningococcal disease: laboratory centre for disease control. CMAJ 1994; 150 (11): 1825–39
8.
go back to reference National Advisory Committee on Immunization, Health Canada. Canadian immunization guide. 6th ed. Ottawa (ON): Canadian Medical Association, 2002 National Advisory Committee on Immunization, Health Canada. Canadian immunization guide. 6th ed. Ottawa (ON): Canadian Medical Association, 2002
9.
go back to reference Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357 (9251): 195–6PubMedCrossRef Ramsay ME, Andrews N, Kaczmarski EB, et al. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357 (9251): 195–6PubMedCrossRef
10.
go back to reference Dionne M, Thibault Paquin L, Fortin C, et al. Bilan de la Campagne de Vaccination centre les infections a meningocoques. Quebec: Direction de la Protection de la santé publique, 1994 Dionne M, Thibault Paquin L, Fortin C, et al. Bilan de la Campagne de Vaccination centre les infections a meningocoques. Quebec: Direction de la Protection de la santé publique, 1994
12.
go back to reference Waterloo Region Community Health Department. Guide to planning a mass immunization campaign: lessons learned from the Waterloo Region meningococcal outbreak, December 1997. Waterloo (ON): Waterloo Regional Community Health Department, 2001 Waterloo Region Community Health Department. Guide to planning a mass immunization campaign: lessons learned from the Waterloo Region meningococcal outbreak, December 1997. Waterloo (ON): Waterloo Regional Community Health Department, 2001
13.
go back to reference Goeree R, Manalich J, Grootendorst P, et al. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995; 18 (6): 455–64PubMed Goeree R, Manalich J, Grootendorst P, et al. Cost analysis of dialysis treatments for end-stage renal disease (ESRD). Clin Invest Med 1995; 18 (6): 455–64PubMed
14.
go back to reference Mohr PE, Feldman JJ, Dunbar JL, et al. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care 2000; 16 (4): 1120–35PubMedCrossRef Mohr PE, Feldman JJ, Dunbar JL, et al. The societal costs of severe to profound hearing loss in the United States. Int J Technol Assess Health Care 2000; 16 (4): 1120–35PubMedCrossRef
15.
go back to reference Durance JP, Warren WK, Kerbel DB, et al. Rehabilitation of below-knee amputees: factors influencing outcome and costs in three programmes. Int Disabil Stud 1989; 11 (3): 127–32PubMedCrossRef Durance JP, Warren WK, Kerbel DB, et al. Rehabilitation of below-knee amputees: factors influencing outcome and costs in three programmes. Int Disabil Stud 1989; 11 (3): 127–32PubMedCrossRef
16.
go back to reference Jacobs P, Bachynsky J, Hall E. A manual of standard costs for pharmacoeconomic studies in Canada: feasibility study. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1995 Jacobs P, Bachynsky J, Hall E. A manual of standard costs for pharmacoeconomic studies in Canada: feasibility study. Ottawa (ON): Canadian Coordinating Office for Health Technology Assessment (CCOHTA), 1995
18.
go back to reference Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 2001; 19 (25–26): 3420–31PubMedCrossRef Parent du Chatelet I, Gessner BD, da Silva A. Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis. Vaccine 2001; 19 (25–26): 3420–31PubMedCrossRef
19.
go back to reference Chippaux JP, Campagne G, Djibo S, et al. Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt. Ann Trop Med Parasitol 1999; 93 (5): 505–10PubMedCrossRef Chippaux JP, Campagne G, Djibo S, et al. Preventive immunisation could reduce the risk of meningococcal epidemics in the African meningitis belt. Ann Trop Med Parasitol 1999; 93 (5): 505–10PubMedCrossRef
21.
go back to reference Canadian Paediatric Society. Invasive meningococcal disease: new developments. Canadian Paediatric Society, 78th Annual Meeting; 2001 Jun 13–17; Vancouver (BC): Medical Education Network Canada, 2001 Canadian Paediatric Society. Invasive meningococcal disease: new developments. Canadian Paediatric Society, 78th Annual Meeting; 2001 Jun 13–17; Vancouver (BC): Medical Education Network Canada, 2001
22.
go back to reference Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001; 15 (1): 155–69PubMedCrossRef Rosenstein NE, Fischer M, Tappero JW. Meningococcal vaccines. Infect Dis Clin North Am 2001; 15 (1): 155–69PubMedCrossRef
23.
go back to reference MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280 (19): 1685–9PubMedCrossRef MacDonald NE, Halperin SA, Law BJ, et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998; 280 (19): 1685–9PubMedCrossRef
Metadata
Title
Cost-Benefit Model Comparing Two Alternative Immunisation Programmes Against Serogroup C Meningococcal Disease
For Quebec Residents Aged 2 Months to 20 Years
Authors
Carol Rancourt
Jean-Pierre Grégoire
W. Robert Simons
Alain Dostie
Publication date
01-04-2003
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 6/2003
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321060-00006

Other articles of this Issue 6/2003

PharmacoEconomics 6/2003 Go to the issue